scholarly journals Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology of Atrial Fibrillation

2021 ◽  
Vol 14 (2) ◽  
Author(s):  
Saira Rafaqat
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome

Impact of the Metabolic Syndrome on Atrial Size in Patients With New-Onset Atrial Fibrillation

Angiology ◽  
2007 ◽  
Vol 58 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Vasilios N. Nicolaou ◽  
John E. Papadakis ◽  
Emmanouil N. Karatzis ◽  
Sofia I. Dermitzaki ◽  
Alexandros K. Tsakiris ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
The Metabolic Syndrome ◽  
Atrial Size ◽  
Onset Atrial Fibrillation ◽  
New Onset

Contrasting effects of diabetes and metabolic syndrome on post-operative atrial fibrillation and in-hospital outcome after cardiac surgery

2013 ◽  
Vol 167 (5) ◽  
pp. 2347-2350 ◽  
Author(s):  
Christopher Hurt ◽  
Augustin Coisne ◽  
Thomas Modine ◽  
Jean-Louis Edme ◽  
Xavier Marechal ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Cardiac Surgery ◽  
Hospital Outcome ◽  
Post Operative Atrial Fibrillation

scholarly journals Effect of epicardial fat and metabolic syndrome on reverse atrial remodeling after ablation for atrial fibrillation

2018 ◽  
Vol 34 (6) ◽  
pp. 607-616 ◽  
Author(s):  
Koyuru Monno ◽  
Yasuo Okumura ◽  
Yuki Saito ◽  
Yoshihiro Aizawa ◽  
Koichi Nagashima ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Epicardial Fat ◽  
Atrial Remodeling

scholarly journals The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Hsiang-Chun Lee ◽  
Shyi-Jang Shin ◽  
Jih-Kai Huang ◽  
Ming-Yen Lin ◽  
Yu-Hsun Lin ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Atrial Remodeling ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Hip Circumference

Abstract Background Negatively charged very-low-density lipoprotein (VLDL-χ) in metabolic syndrome (MetS) patients exerts cytotoxic effects on endothelial cells and atrial myocytes. Atrial cardiomyopathy, manifested by atrial remodeling with a dilated diameter, contributes to atrial fibrillation pathogenesis and predicts atrial fibrillation development. The correlation of VLDL-χ with atrial remodeling is unknown. This study investigated the association between VLDL-χ and remodeling of left atrium. Methods Consecutively, 87 MetS and 80 non-MetS individuals between 23 and 74 years old (50.6% men) without overt cardiovascular diseases were included in the prospective cohort study. Blood samples were collected while fasting and postprandially (at 0.5, 1, 2, and 4 h after a unified meal). VLDL was isolated by ultracentrifugation; the percentile concentration of VLDL-χ (%) was determined by ultra-performance liquid chromatography. The correlations of left atrium diameter (LAD) with variables including VLDL-χ, LDL-C, HDL-C, triglycerides, glucose, and blood pressure, were analyzed by multiple linear regression models. A hierarchical linear model was conducted to test the independencies of each variable’s correlation with LAD. Results The mean LAD was 3.4 ± 0.5 cm in non-MetS subjects and 3.9 ± 0.5 cm in MetS patients (P < 0.01). None of the fasting lipid profiles were associated with LAD. VLDL-χ, BMI, waist circumference, hip circumference, and blood pressure were positively correlated with LAD (all P < 0.05) after adjustment for age and sex. Significant interactions between VLDL-χ and blood pressure, waist circumference, and hip circumference were observed. When adjusted for obesity- and blood pressure-related variables, 2-h postprandial VLDL-χ (mean 1.30 ± 0.61%) showed a positive correlation with LAD in MetS patients. Each 1% VLDL-χ increase was estimated to increase LAD by 0.23 cm. Conclusions Postprandial VLDL-χ is associated with atrial remodeling particularly in the MetS group. VLDL-χ is a novel biomarker and may be a therapeutic target for atrial cardiomyopathy in MetS patients. Trial registration ISRCTN 69295295. Retrospectively registered 9 June 2020.

scholarly journals What Do We Currently Know About Metabolic Syndrome and Atrial Fibrillation?

2013 ◽  
Vol 36 (11) ◽  
pp. 654-662 ◽  
Author(s):  
Marijana Tadic ◽  
Branislava Ivanovic ◽  
Cesare Cuspidi
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome

COULD EARLY DIAGNOSIS OF METABOLIC SYNDROME LOWER THE INCIDENCE OF ATRIAL FIBRILLATION IN HYPERTENSIVE PATIENTS?: PP.28.123

2010 ◽  
Vol 28 ◽  
pp. e485
Author(s):  
E Belu ◽  
R Musetescu ◽  
DD Ionescu ◽  
AE Musetescu ◽  
V Belu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Early Diagnosis ◽  
Hypertensive Patients

scholarly journals Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study

2010 ◽  
Vol 159 (5) ◽  
pp. 850-856 ◽  
Author(s):  
Alanna M. Chamberlain ◽  
Sunil K. Agarwal ◽  
Marietta Ambrose ◽  
Aaron R. Folsom ◽  
Elsayed Z. Soliman ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Atherosclerosis Risk In Communities ◽  
Atherosclerosis Risk ◽  
Blacks And Whites ◽  
Aric Study

Metabolic syndrome and atrial fibrillation in patients with essential hypertension

2013 ◽  
Vol 23 (2) ◽  
pp. 109-114 ◽  
Author(s):  
G. Vyssoulis ◽  
E. Karpanou ◽  
D. Adamopoulos ◽  
S.-M. Kyvelou ◽  
V. Tzamou ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Essential Hypertension
Sign in / Sign up

Export Citation Format

Share Document